Lanre News

Reporting to NOBODY but YOU.

Monkeys Infected With COVID-19 Developed Short-Term Immunity ― Study

Test monkeys infected with the novel coronavirus responsible for the COVID-19 pandemic were protected from reinfection for up to 28 days later, a Chinese study out Thursday in the journal Science said.

While the monkeys displayed initial immunity, it’s unclear how long such immunity will last in humans – it will be necessary to wait months, or even years, to know if the millions of people infected at the start of the pandemic are protected from re-infection.

Scientists from Peking Union Medical College performed an experiment on rhesus macaques, often used because of their similarities to humans, to find out if they have a short-term immunity to the virus.

READ MORE NEWS:

Six rhesus macaques were infected in their trachea with a dose of the SARS-CoV-2 virus. They developed mild to moderate symptoms, and took about two weeks to recover.

Twenty-eight days after the first infection, four of the six monkeys received another dose of virus, but this time, despite a brief rise in temperature, they showed no sign of reinfection, the study authors wrote.

By taking frequent samples the researchers discovered that the peak viral load was reached three days after the monkeys were infected. 

The monkeys showed a stronger immune response after the first infection, producing more so-called neutralising antibodies which may have protected them against short-term reinfection, the scientists wrote.

More experiments are needed to see how long this immune defense remains, the authors said.

Ajimobi moment with family before demise

Click to read more news…

Lanre News | Latest News in Nigeria | Africa | Around the World.

Freelance Writers and Employers, visit our sister site [www.lanrewriter.com] to connect.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x
%d bloggers like this:
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept